4 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
| Phase 2 | 3 | Terminated 3 |
Follow dactolisib: new trials by email Literature Review of dactolisib trials Research Report on dactolisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer BEZ235, Prednisone, Abiraterone acetate - Castrate-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Charles Ryan | 6 | 2013-01-31 | 2018-03-27 |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer BEZ235, Paclitaxel - Inoperable Locally Advanced Breast Cancer, Metastatic Breast Cancer (MBC) | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 18 | 2012-01-30 | 2020-12-08 |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors BEZ235, Everolimus - Cancer | Phase 1 | Terminated | University of Cincinnati | 19 | 2012-01-01 | 2017-08-23 |
| BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) BEZ235 - Renal Cancer | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 10 | 2011-10-01 | 2016-02-29 |
Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroendocrine Tumors (1)
Charles Ryan (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · University of Cincinnati (1)
United States (3) · France (1) · Spain (1)
Ana Molina, MD (1) · Charles Ryan, MD (1) · John Morris, MD (1)